Amylyx Pharmaceuticals, INC Form 4 insider transactions

Chief Medical Officer Camille L. Bedrosian reports acquisition of common stock and stock options in Amylyx Pharmaceuticals.

Bernhardt G. Zeiher, a director of Amylyx Pharmaceuticals, acquired 50,000 stock options on March 14, 2024, according to a recent SEC filing.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, sold 4,135 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports the sale of shares to cover tax obligations related to vesting restricted stock units and a transfer of shares to a trust.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 1,540 shares of common stock on March 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Chief Financial Officer of Amylyx Pharmaceuticals, James M. Frates, reports acquisition of 40,000 shares of common stock and 60,000 stock options.

Joshua Cohen, Co-CEO of Amylyx Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Co-CEO of Amylyx Pharmaceuticals, Justin B. Klee, reports the acquisition of restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, receives restricted stock units and stock options.

Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 2,838 shares of common stock on February 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.